(LLY) Eli Lilly and Company BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LLY) Eli Lilly and Company Bundle
See the Bigger Picture
This Eli Lilly and Company BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. This page already shows a real preview of the report content, so you can see the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
Mounjaro, >$11B 2024 sales
Mounjaro generated about $11.5 billion in 2024 sales, making it Eli Lilly and Company’s top diabetes growth engine. It has a leading position in the incretin class, which kept expanding fast in 2024 and 2025. That mix of strong sales, share gains, and rapid category growth fits a classic Star in the BCG Matrix.
Zepbound, >$4B 2024 sales
Zepbound crossed $4 billion in 2024 sales, showing how fast Eli Lilly and Company built its obesity franchise after launch. Demand kept rising in 2025 as U.S. obesity prevalence stayed near 42% of adults and global access broadened, so the market is still expanding. With high growth and strong share, Zepbound fits the Star quadrant in Eli Lilly and Company’s BCG matrix.
Verzenio, >$5B 2024 sales
Verzenio is Eli Lilly and Company’s key oncology star, with 2024 sales of about $5.3 billion, up 33% year over year. It treats HR+, HER2- breast cancer in both metastatic and early settings, which keeps demand broad and durable. That growth has kept Verzenio in a leading market position and made it Lilly’s main cancer growth driver.
Taltz, nearly $3B 2024 sales
Taltz fits Star status in Eli Lilly and Company BCG Matrix: 2024 sales were nearly $3B, powered by psoriasis and psoriatic arthritis use. The immunology market is still growing, so strong brand demand and broad indications support high share in a large, expanding category.
- Taltz: nearly $3B 2024 sales
- Multiple immunology indications
- Psoriasis and psoriatic arthritis
- Large, expanding specialty market
Jardiance, blockbuster cardio-renal franchise
Jardiance is a Star-like asset for Eli Lilly and Company: it posted about $8.6 billion in 2024 global sales, driven by type 2 diabetes, heart failure, and CKD use. Lilly and Boehringer Ingelheim still benefit from strong scale, broad label reach, and durable demand, so the franchise keeps showing market leadership and steady growth.
2024 sales: about $8.6 billion.
Multi-use demand: diabetes, HF, CKD.
Alliance-backed scale supports leadership.
Lilly’s Star Brands Are Powering Growth Across Key Markets
Mounjaro, Zepbound, Verzenio, Taltz, and Jardiance all fit Stars in Eli Lilly and Company’s BCG Matrix because each combines strong share with a fast-growing market. Mounjaro led with about $11.5 billion in 2024 sales, Zepbound topped $4 billion, Verzenio reached about $5.3 billion, Taltz was nearly $3 billion, and Jardiance was about $8.6 billion. Their 2025 demand stayed firm across diabetes, obesity, oncology, immunology, and cardio-renal care.
| Asset | 2024 Sales | Star Driver |
|---|---|---|
| Mounjaro | $11.5B | Incretin share gain |
| Zepbound | $4B+ | Obesity growth |
| Verzenio | $5.3B | Oncology leadership |
| Taltz | ~$3B | Immunology demand |
| Jardiance | $8.6B | Multi-use scale |
What is included in the product
Detailed Word Document
Eli Lilly BCG Matrix: clear quadrant view of drugs to invest in, hold, or divest.
Editable Excel File
Eli Lilly BCG Matrix: one-page view of each business unit for quick, clear strategic decisions
Reference Sources
Eli Lilly and Company Reference Sources provide a credible audit trail that supports faster, more confident decisions.
Cash Cows
Trulicity, >$5B 2024 sales
Trulicity brought in $5.25B in 2024 sales, down from $5.56B in 2023, so it is still a major revenue engine for Eli Lilly and Company. With GLP-1 rivals like Novo Nordisk's Ozempic and Eli Lilly and Company's own Mounjaro taking share, growth has slowed and stayed negative. That mature, high-cash, low-growth profile fits a Cash Cow.
Humalog family, legacy rapid insulin
Humalog, launched in 1996, is Lilly's legacy rapid insulin with deep prescriber familiarity and long market use. Growth is now low, but it still adds steady cash as diabetes demand stays large. In 2024, Lilly posted $45.0 billion in revenue, and Humalog remains a mature cash engine inside that base.
Humulin line, long-established human insulin
Humulin is a classic mature diabetes line: low growth, stable demand, and steady cash generation with little extra capital. In Eli Lilly and Company’s 2024 base, total revenue was $45.0 billion, and legacy insulin products like Humulin help fund newer growth drugs while the market stays structurally flat.
Basaglar, mature insulin glargine
Basaglar is Lilly’s insulin glargine U-100 biosimilar in a mature basal-insulin market. Demand is steady, but growth is capped by heavy competition from long-acting insulins and biosimilars. That makes it a classic Cash Cow: low growth, reliable cash flow.
- Stable volume
- Low category growth
- Strong cash generation
- Price pressure risk
In 2025, the global insulin glargine market remained dominated by cost-focused switching, so Basaglar can still throw off cash even without fast expansion.
Emgality, migraine brand
Emgality is a mature migraine and cluster headache brand, approved in 2018 for migraine prevention and in 2019 for episodic cluster headache. With an established patient base and no launch-phase spend, its growth is steadier and fits Eli Lilly and Company’s Cash Cow bucket more than a Star.
- Mature brand, not early-stage
- Broad U.S. migraine base
- Lower growth, steadier cash flow
- Supports profit, not breakout growth
Eli Lilly’s Cash Cows Keep the Cash Flowing
Eli Lilly and Company’s Cash Cows are mature brands with steady demand and limited growth, led by Trulicity, Humalog, Humulin, Basaglar, and Emgality. Trulicity still posted $5.25B in 2024 sales, while Eli Lilly and Company totaled $45.0B in revenue, so these lines still fund newer launches. Their value comes from cash, not expansion.
| Brand | Signal |
|---|---|
| Trulicity | $5.25B sales |
| Humalog | Mature insulin |
| Humulin | Stable demand |
| Basaglar | Price pressured |
| Emgality | Steady cash |
Get Your Copy
Eli Lilly and Company Reference Sources
The Eli Lilly and Company BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no hidden pages, demo sections, or watermarks—just the complete, polished report. It’s ready to download, use, and share right away.
Dogs
Cymbalta, generic since 2014
Cymbalta is an older SNRI that lost U.S. exclusivity in 2013, and generics have dominated since 2014. Eli Lilly and Company’s branded share is now minimal, with sales pressure coming from low-cost copies in a mature antidepressant and pain market. That mix of low growth and low share fits the Dogs bucket in the BCG Matrix.
Zyprexa, generic since 2011
Zyprexa has been generic since 2011, so Eli Lilly and Company now treats it as a legacy brand, not a growth engine. In a mature antipsychotic market, sales growth is minimal and pricing pressure is high. That profile fits a Dog in the BCG Matrix: low growth, weak strategic priority, and limited cash-generation upside.
Alimta, patent expiry era asset
Alimta (pemetrexed) is a clear Dog for Eli Lilly and Company: U.S. patent protection ended, and generic rivals have cut pricing and share for years. Demand in NSCLC and mesothelioma is mature, so growth is weak and the product no longer supports high-margin economics. In 2025/2026, Alimta contributes only a small, declining legacy stream, not a growth driver.
Forteo, biosimilar pressure
Forteo is a classic Dog in Eli Lilly and Company’s BCG Matrix: it sits in a low-growth osteoporosis market and faces heavy generic and biosimilar pressure. U.S. exclusivity ended in 2019, and teriparatide copies have kept pricing power weak, so the brand no longer supports meaningful growth.
- Low growth, high rivalry
- Generic pressure cuts margins
- Weak pricing power signals Dog
Cialis, generic since 2018
Cialis fits Dogs: it lost U.S. exclusivity in 2018, so Lilly no longer has the pricing power that once drove growth. By 2025, the erectile dysfunction market is mature and crowded, with low growth and many tadalafil generics, so share and margins stay weak. That makes Cialis a legacy cash tail, not a BCG growth asset.
- Generic since 2018
- Mature, crowded ED market
- Low growth, weak share
Eli Lilly’s Legacy Brands Are Losing Their Bite
In Eli Lilly and Company, Dogs are legacy brands with low growth and weak pricing power after patent loss. Cymbalta, Zyprexa, Alimta, Forteo, and Cialis now face generic-led erosion, so they add limited strategic value in 2025/2026.
| Brand | Dog signal |
|---|---|
| Cymbalta | 2013 loss, generic-led |
| Zyprexa | 2011 loss, mature |
| Alimta | Declining legacy sales |
| Forteo | 2019 loss, weak price |
| Cialis | 2018 loss, crowded |
Question Marks
Kisunla, 2024 launch
Kisunla (donanemab) launched in July 2024 for early symptomatic Alzheimer’s disease. The market is huge: about 6.9 million Americans age 65+ live with Alzheimer’s, but Lilly is still in the early phase of uptake and share building. With high long-term potential and still modest current penetration versus Leqembi, Kisunla fits the Question Mark category.
Jaypirca, 2023 launch
Jaypirca, launched in 2023, is Eli Lilly and Company’s newer BTK inhibitor for B-cell cancers, so it fits a Question Mark in the BCG matrix: high-growth field, still small share. BTK inhibitors remain a large market, with AbbVie and Johnson & Johnson still setting the pace. Eli Lilly and Company is still building Jaypirca uptake as it competes in mantle cell and chronic lymphocytic leukemia.
Omvoh, 2023 launch
Omvoh, launched in 2023, is still in the build phase for ulcerative colitis and Crohn’s disease, two specialty markets with large, growing patient pools. Lilly is scaling against entrenched immunology brands like AbbVie and Johnson & Johnson, so share is still small versus the market size. That mix of low share and growth fits a Question Mark in the BCG Matrix.
Ebglyss, 2024 launch
Ebglyss, launched in 2024, gives Eli Lilly and Company a real shot in atopic dermatitis, a market that affects about 16.5 million U.S. adults and roughly 101 million people worldwide. Still, the brand is early in adoption, so its sales base is small versus mature dermatology biologics. That keeps Ebglyss in the Question Mark box.
- 2024 launch
- Large, growing AD market
- Early commercial penetration
- Question Mark status
Retevmo, niche RET oncology asset
Retevmo targets rare RET-driven cancers, including RET fusions in about 1% to 2% of NSCLC and RET-mutant medullary thyroid cancer, so its addressable pool is small. Lilly’s 2025 sales base is still limited versus its big franchises, even if the niche is growing. That puts Retevmo in Question Mark, not Star.
- Small biomarker pool
- Growing but narrow market
- Limited current share
Lilly’s Question Marks: Early Growth, Big Upside
Kisunla, Jaypirca, Omvoh, Ebglyss, and Retevmo are Eli Lilly and Company Question Marks: each sits in a large or growing niche, but 2025 uptake is still early versus entrenched rivals. Lilly is still spending to build share, so these brands have upside, but not enough scale yet to be Stars.
| Brand | 2025 read |
|---|---|
| Kisunla | Early AD launch |
| Jaypirca | Small BTK share |
| Omvoh | Build phase |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.